Don Faller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Don Faller has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
M. P. Ryan
Department of Pharmacology, University College Dublin, Blackrock, Ireland
2 shared publicationsA. K. Keenan
Department of Pharmacology, University College, Belfield, Dublin, Ireland
1 shared publication- Akinlolu Akande
Modelling & Computation for Health And Society (MOCHAS), Atlantic Technological University, Ash Lane, Ballytivnan, Sligo, F91 YW50, Ireland
1 shared publication Ann Mulvihill
Athlone Institute of Technology, Athlone, Westmeath, Ireland
1 shared publication- Anne M. Friel
Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
1 shared publication C. Doolan
University College
1 shared publication
Latest Publications
- Open Access
- 1 July 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (7) , 3469-3485
Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro
Background/Aim: Isothiocyanates (ITCs) are phytochemicals with potential cancer-preventative properties derived from the breakdown of glucosinolates that exist in cruciferous vegetables. Studies, to date, have demonstrated that various ITCs possess the ability to act as anticancer agents in different cancer types. This study investigated the anticancer properties of dietary ITCs (allyl-ITC, benzyl-ITC, phenylethyl-ITC) and synthetic (phenylbutyl-ITC and phenylhexyl-ITC) on liver and prostate carcinoma cells in vitro. Materials and Methods: The effects of ITCs on cellular viability, migration, invasion, clonogenicity, apoptosis induction and reactive oxygen species generation were assessed in HepG2, DU145 and 22Rv1 cells. Results: All ITCs reduced metabolic activity in each cell line with the most significant being phenylethyl-ITC. Both dietary and synthetic ITCs suppressed the migratory and invasive potential of all cell lines, inhibited colony-forming capability and induced apoptosis. Phenylethyl-ITC exposure resulted in the significant generation of reactive oxygen species. Conclusion: These data highlight the potential advantages of utilizing ITCs to delay the carcinogenic process and the potential for dietary and synthetic ITCs to act as anticancer agents.
- 1 July 2019
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 39 (7) , 3469-3485
Open AccessNatural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro
Background/Aim: Isothiocyanates (ITCs) are phytochemicals with potential cancer-preventative properties derived from the breakdown of glucosinolates that exist in cruciferous vegetables. Studies, to date, have demonstrated that various ITCs possess the ability to act as anticancer agents in different cancer types. This study investigated the anticancer properties of dietary ITCs (allyl-ITC, benzyl-ITC, phenylethyl-ITC) and synthetic (phenylbutyl-ITC and phenylhexyl-ITC) on liver and prostate carcinoma cells in vitro. Materials and Methods: The effects of ITCs on cellular viability, migration, invasion, clonogenicity, apoptosis induction and reactive oxygen species generation were assessed in HepG2, DU145 and 22Rv1 cells. Results: All ITCs reduced metabolic activity in each cell line with the most significant being phenylethyl-ITC. Both dietary and synthetic ITCs suppressed the migratory and invasive potential of all cell lines, inhibited colony-forming capability and induced apoptosis. Phenylethyl-ITC exposure resulted in the significant generation of reactive oxygen species. Conclusion: These data highlight the potential advantages of utilizing ITCs to delay the carcinogenic process and the potential for dietary and synthetic ITCs to act as anticancer agents.
- 10 January 2018
- Published by Springer Nature in MRS Advances
- Vol. 3 (12) , 631-636
Studying Student Experience of Technology Enhanced Assessment Methods (TEAM) in Science and Health in Ireland
- 10 January 2018
- Published by Springer Nature in MRS Advances
- Vol. 3 (12) , 631-636
Studying Student Experience of Technology Enhanced Assessment Methods (TEAM) in Science and Health in Ireland
- 1 July 1995
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 269 (1) , C148-C155
Evidence for location of the CFTR in human placental apical membrane vesicles
Ion transport (36Cl uptake) and immunochemical studies were undertaken to detect the cystic fibrosis transmembrane conductance regulator (CFTR) in apical membrane vesicles prepared from human placenta. 36Cl uptake into membrane vesicles was studied in the absence and presence of inwardly directed potassium gradients and valinomycin (Ko = Ki and Ko > Ki, where Ko is potassium concentration outside and Ki is potassium concentration inside the vesicles). The sensitivities of 36Cl uptake to the inhibitors 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), bumetanide, and diphenylamine-2-carboxylate were investigated. Each compound significantly inhibited uptake under both sets of conditions. Additional inhibition of 36Cl uptake was found when the compounds were added together, indicating that they were acting at least partly on different components of the 36Cl uptake. The DIDS- and bumetanide-insensitive component of transport was more selective for Cl than I. These findings suggested that this component may, at least in part, represent Cl transport via CFTR. Addition of adenosine 5'-O-(3-thiotriphosphate) (0.8 mM) led to a decrease in total 36Cl uptake but masked in the overall decrease was an increase in the DIDS- and bumetanide-insensitive component of 36Cl uptake. Western blot analysis of the apical membrane proteins with an antibody specific for a region of human CFTR detected a protein band of approximately 190 kDa. These ion transport and immunochemical studies provide evidence that CFTR is located in human placental apical membrane vesicles.
- 1 July 1995
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 269 (1) , C148-C155
Evidence for location of the CFTR in human placental apical membrane vesicles
Ion transport (36Cl uptake) and immunochemical studies were undertaken to detect the cystic fibrosis transmembrane conductance regulator (CFTR) in apical membrane vesicles prepared from human placenta. 36Cl uptake into membrane vesicles was studied in the absence and presence of inwardly directed potassium gradients and valinomycin (Ko = Ki and Ko > Ki, where Ko is potassium concentration outside and Ki is potassium concentration inside the vesicles). The sensitivities of 36Cl uptake to the inhibitors 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), bumetanide, and diphenylamine-2-carboxylate were investigated. Each compound significantly inhibited uptake under both sets of conditions. Additional inhibition of 36Cl uptake was found when the compounds were added together, indicating that they were acting at least partly on different components of the 36Cl uptake. The DIDS- and bumetanide-insensitive component of transport was more selective for Cl than I. These findings suggested that this component may, at least in part, represent Cl transport via CFTR. Addition of adenosine 5'-O-(3-thiotriphosphate) (0.8 mM) led to a decrease in total 36Cl uptake but masked in the overall decrease was an increase in the DIDS- and bumetanide-insensitive component of 36Cl uptake. Western blot analysis of the apical membrane proteins with an antibody specific for a region of human CFTR detected a protein band of approximately 190 kDa. These ion transport and immunochemical studies provide evidence that CFTR is located in human placental apical membrane vesicles.
- 2 March 1994
- Published by Elsevier in Biochemical Pharmacology
- Vol. 47 (5) , 757-761
Amiloride-sensitive sodium uptake into human placental brush border membrane vesicles
- 2 March 1994
- Published by Elsevier in Biochemical Pharmacology
- Vol. 47 (5) , 757-761
Amiloride-sensitive sodium uptake into human placental brush border membrane vesicles
- 1 January 1991
- Published by Springer Nature
- Vol. 290, 361-363
Human Placental Membrane Vesicles as Models for Investigation of Cystic Fibrosis
- 1 January 1991
- Published by Springer Nature
- Vol. 290, 361-363
Human Placental Membrane Vesicles as Models for Investigation of Cystic Fibrosis